

# Transparent nanocrystalline yttria-stabilized-zirconia calvarium prosthesis

Yasaman Damestani, BS<sup>a</sup>, Carissa L. Reynolds, BS<sup>a</sup>, Jenny Szu, BS<sup>b</sup>, Mike S. Hsu, MS<sup>b</sup>,  
Yasuhiro Kodera, PhD<sup>c</sup>, Devin K. Binder, MD, PhD<sup>a,b</sup>, B. Hyle Park, PhD<sup>a</sup>,  
Javier E. Garay, PhD<sup>c,d</sup>, Masaru P. Rao, PhD<sup>a,c,d</sup>, Guillermo Aguilar, PhD<sup>a,c,\*</sup>

<sup>a</sup>Department of Bioengineering, University of California, Riverside, CA, USA

<sup>b</sup>Division of Biomedical Sciences, University of California, Riverside, CA, USA

<sup>c</sup>Department of Mechanical Engineering, University of California, Riverside, CA, USA

<sup>d</sup>Materials Science and Engineering Program, University of California, Riverside, CA, USA

Received 8 March 2013; accepted 12 August 2013

## Abstract

Laser-based diagnostics and therapeutics show promise for many neurological disorders. However, the poor transparency of cranial bone (calvaria) limits the spatial resolution and interaction depth that can be achieved, thus constraining opportunity in this regard. Herein, we report preliminary results from efforts seeking to address this limitation through use of novel transparent cranial implants made from nanocrystalline yttria-stabilized zirconia (nc-YSZ). Using optical coherence tomography (OCT) imaging of underlying brain in an acute murine model, we show that signal strength is improved when imaging through nc-YSZ implants relative to native cranium. As such, this provides initial evidence supporting the feasibility of nc-YSZ as a transparent cranial implant material. Furthermore, it represents a crucial first step towards realization of an innovative new concept we are developing, which seeks to eventually provide a clinically-viable means for optically accessing the brain, on-demand, over large areas, and on a chronically-recurring basis, without need for repeated craniectomies.

**From the Clinical Editor:** In this study, transparent nanocrystalline yttria-stabilized-zirconia is used as an experimental “cranium prosthesis” material, enabling the replacement of segments of cranial bone with a material that allows for optical access to the brain on a recurrent basis using optical imaging methods such as OCT.

© 2013 Elsevier Inc. All rights reserved.

**Key words:** Optical neuroimaging; Calvarial prosthesis

Laser-based techniques have shown promise for enhancing the diagnosis and treatment of many neurological disorders, including cerebral edema, stroke, and cancer, among others.<sup>1–3</sup> However, the poor transparency of cranial bone to clinically-relevant laser wavelengths (i.e.  $\lambda = 550\text{--}1300$  nm) typically necessitates use of invasive craniectomies to provide optical access to the brain. This constrains the ultimate utility of such techniques, particularly for applications where chronically-recurring access over large areas is required.

Recent studies have demonstrated potential for increasing cranial transparency through thinning.<sup>4,5</sup> However, since this diminishes protection for the brain, associated safety concerns

may preclude opportunity for translation of such techniques to the clinic. Other studies have reported use of transparent glass-based implants, either in place of cranium,<sup>6</sup> or as an overlay to increase the rigidity of thinned-skull preparations.<sup>7</sup> However, the extremely low fracture toughness of typical glasses ( $K_{IC} = 0.7\text{--}0.9$  MPa · m<sup>1/2</sup>) increases potential for catastrophic failure by fracture, which will limit opportunity for use of such implants beyond the laboratory. This, therefore, motivates the search for alternate materials that will provide better potential for eventual clinical use.

While a number of synthetic materials have been evaluated for use in calvarial reconstruction, including titanium, alumina, and acrylic,<sup>8</sup> none provide the requisite combination of transparency and toughness required for clinically-viable transparent cranial implants. Yttria-stabilized zirconia (YSZ) represents an attractive alternative, due to its relatively high toughness ( $K_{IC} \sim 8$  MPa · m<sup>1/2</sup>), as well as its proven biocompatibility in dental and orthopedic applications. However, YSZ is typically opaque, thus precluding its consideration thus far.

**Research Support:** This research was supported, in part, by the University of California, Riverside Chancellor's Strategic Research Initiative (PI: G. Aguilar).

\*Corresponding author: University of California, Riverside, CA, USA.  
E-mail address: [gaguilar@engr.ucr.edu](mailto:gaguilar@engr.ucr.edu) (G. Aguilar).

1549-9634/\$ – see front matter © 2013 Elsevier Inc. All rights reserved.  
<http://dx.doi.org/10.1016/j.nano.2013.08.002>




Figure 1. Transparent nc-YSZ cranial implants: (A) Photograph of implant placed on printed scale to demonstrate transparency; (B) schematic of craniectomy location on murine cranium; (C) photograph of craniectomy with dura mater left intact; and (D) photograph after implant placement. Note: Implant opacity in (D) is flash-induced image artifact.

Herein, we report the preliminary evaluation of novel transparent nanocrystalline YSZ (nc-YSZ) cranial implants that seek to provide new opportunity in this regard. Using optical coherence tomography (OCT), we demonstrate the initial feasibility of nc-YSZ cranial implants within the context of cortical imaging in an acute murine model. We then discuss the implications of these implants with regard to a broader concept we are developing, which may eventually serve as a critical enabler for the wider use of lasers in the diagnosis and treatment of neurological disorders.

## Methods

The transparent nc-YSZ cranial implants were made possible through use of the CAPAD process,<sup>9</sup> an emerging technique that enables reduction of internal porosity to nanometric dimensions, and thus, reduction of the optical scattering that renders typical YSZ opaque.<sup>10</sup> Densified nc-YSZ blanks were polished, annealed, and machined into rectangular implants with dimensions of  $2.1 \times 4.2 \times 0.2 \text{ mm}^3$ . Figure 1, A demonstrates the transparency of the finished implants.

As shown in Figures 1, B–D, right-sided craniectomies were performed on anesthetized mice, followed by fixation of nc-YSZ

implants to the surrounding skull with dental cement. The left-side of the cranium was left unmodified to serve as a control. All animal experiments were conducted under a protocol approved by the University of California, Riverside Institutional Animal Care and Use Committee (#2010-0018), and in conformance with the *Guide for the Care and Use of Laboratory Animals* published by the National Institutes of Health (NIH Publication No. 85-23, revised 1996).

To evaluate initial nc-YSZ implant feasibility, OCT was used as a representative optical imaging modality.<sup>11,12</sup> Imaging was performed over a  $2 \times 2 \text{ mm}^2$  area on the coronal position for both the nc-YSZ implant and the native cranium. Further details regarding nc-YSZ fabrication, implantation, and OCT imaging can be found in the *Supplemental Materials*.

## Results

Figure 2 shows cross-sectional OCT images of murine brain through native cranium (left of midline) and nc-YSZ implant (right of midline) in the same animal. Detailed description of the image interpretation is presented in the *Supplemental Materials*. The enhanced transparency of the nc-YSZ implant is evidenced




Figure 2. OCT cross-sectional image of murine brain (coronal view) through: (Left) Native cranium; and (Right) nc-YSZ implant.

by the opportunity it provides for imaging of sub-cortical white matter (darker band at bottom of image, right of midline), which is nearly imperceptible when imaging through native cranium (left of midline).

Figure 3 shows OCT signal strengths as a function of depth from the cortical surface when imaging through native cranium and nc-YSZ, respectively. As would be expected, intensity decays with depth for both, aside from the increase associated with sub-cortical white matter. However, signal strength at nearly every depth is significantly higher when imaging through the nc-YSZ implant, further demonstrating the enhanced imaging performance.

## Discussion

Figures 2 and 3 demonstrate that OCT imaging through nc-YSZ implants is indeed possible and provides greater signal strength than imaging through native cranium. This, therefore, establishes the initial feasibility of nc-YSZ as a transparent cranial implant material for optical diagnostic and therapeutic applications. Moreover, when coupled with the high toughness of nc-YSZ, this suggests unique potential for eventual clinical application.

However, before such potential can be realized, further studies are required to evaluate the long-term biological response to nc-YSZ implants, since: a) the demands imposed upon cranial implants differ from those in dental and orthopedic applications; and b) the need for transparency will require minimization of fibrosis and/or bone regrowth over the implant. Regarding the latter, it may ultimately be more beneficial to thin the cranium significantly and then cover with a nc-YSZ implant, as Shih et al. recently demonstrated for glass-based implants.<sup>13</sup>

Although beyond the scope of the current study, it is important to also briefly consider the effect of the scalp on imaging performance, since: a) coverage of the nc-YSZ implant with native scalp will be preferred for applications requiring long-term implantation; and b) repeated scalp removal is unlikely to be desirable when chronically-recurring access over large areas is required. Optical clearing agents (OCAs) represent a compelling possibility in this regard, since they have been shown to provide capability for temporarily rendering skin transparent on demand.<sup>14–17</sup> When used in conjunction with nc-YSZ implants, we envision potential for realization of an innovative new concept




Figure 3. OCT signal strength depth profile for imaging through native cranium vs. nc-YSZ implant.

we have named Windows to the Brain (WttB), which seeks to eventually provide opportunity for optical accessing the brain, on-demand, over large areas, and on a chronically-recurring basis, without need for repeated craniectomies or scalp removal.

While the current study represents only the first step towards realization of the WttB concept, it is instructive to consider the opportunities this may eventually afford. For example, opportunity may arise for chronic monitoring of cerebral edema, which is largely precluded by the invasiveness of current techniques.<sup>18</sup> Similarly, it may enable chronic monitoring and more precise targeting of photodynamic therapies for residual gliomas,<sup>19</sup> which could prolong survival and improve quality of life for many suffering from brain cancer. Finally, it could provide a platform for development of new optical neuromodulation modalities, with potential applications ranging from fundamental neurophysiology studies to clinical psychiatry.<sup>20</sup>

## Acknowledgments

The authors thank Ms. Melissa Eberle for her contribution to OCT data collection, and Prof. Elaine Haberer and Mr. Mohammad Shahriar Zaman for their contribution to nc-YSZ absorption characterization.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.nano.2013.08.002>.

## References

1. Naeser MA, Hamblin MR. Potential for transcranial laser or LED therapy to treat stroke, traumatic brain injury, and neurodegenerative disease. *Photomedicine and Laser Surgery* 2011;**29**:443-6.
2. Mathews MS, Chighvinadze D, Gach HM, Uzal FA, Madsen SJ, Hirschberg H. Cerebral edema following photodynamic therapy using endogenous and exogenous photosensitizers in normal brain. *Lasers Surg Med* 2011;**43**:892-900.
3. Juzenas P, Chen W, Sun YP, Coelho MAN, Generalov R, et al. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. *Adv Drug Deliver Rev* 2008;**60**:1600-14.
4. Szu JI, Eberle MM, Reynolds CL, Hsu MS, Wang Y, et al. Thinned-skull cortical window technique for in vivo optical coherence tomography imaging. *Journal of visualized experiments, JoVE* 2012:e50053.
5. Kelly EA, Majewska AK. Chronic imaging of mouse visual cortex using a thinned-skull preparation. *J Vis Exp* 2010;**44**:e2060, <http://dx.doi.org/10.3791/2060>.
6. Mostany R, Portera-Cailliau C. A craniotomy surgery procedure for chronic brain imaging. *J Vis Exp* 2008;**12**:e680, <http://dx.doi.org/10.3791/680>.
7. Drew PJ, Shih AY, Driscoll JD, Knutsen PM, Blinder P, et al. Chronic optical access through a polished and reinforced thinned skull. *Nature methods* 2010;**7**:981-4.
8. Hulbert S. The use of alumina and zirconia in surgical implants. In: Hench LL, Wilson J, editors. *An introduction to bioceramics*. Singapore: World Scientific; 1993. p. 25-40.
9. Casolco R, Xu J, Garay JE. Transparent/translucent polycrystalline nanostructured yttria stabilized zirconia with varying colors. *Scr Mater* 2008;**58**:516-9.
10. Alaniz JE, Perez-Gutierrez FG, Aguilar G, Garay JE. Optical properties of transparent nanocrystalline yttria stabilized zirconia. *Optical Materials* 2009;**32**:62-8.
11. Jeon SW, Shure MA, Baker KB, Huang D, Rollins AM, et al. A feasibility study of optical coherence tomography for guiding deep brain probes. *Journal of neuroscience methods* 2006;**154**:96-101.
12. Yaroslavsky AN, Schulze PC, Yaroslavsky IV, Schober R, Ulrich F, Schwarzmaier HJ. Optical properties of selected native and coagulated human brain tissues in vitro in the visible and near infrared spectral range. *Phys Med Biol* 2002;**47**:2059-73.
13. Shih AY, Mateo C, Drew PJ, Tsai PS, Kleinfeld D. A polished and reinforced thinned-skull window for long-term imaging of the mouse brain. *J Vis Exp* 2012;**61**:e3742, <http://dx.doi.org/10.3791/3742>.
14. He Y, Wang RK. Dynamic optical clearing effect of tissue impregnated with hyperosmotic agents and studied with optical coherence tomography. *J Biomed Opt* 2004;**9**:200-6.
15. Cicchi R, Sampson D, Massi D, Pavone F. Contrast and depth enhancement in two-photon microscopy of human skin ex vivo by use of optical clearing agents. *Opt Express* 2005;**13**:2337-44.
16. Tuchin VV, Maksimova IL, Zimnyakov DA, Kon IL, Mavlyutov AH, Mishin AA. Light propagation in tissues with controlled optical properties. *Journal of Biomedical Optics* 1997;**2**:401-17.
17. Vargas G, Chan KF, Thomsen SL, Welch AJ. Use of osmotically active agents to alter optical properties of tissue: effects on the detected fluorescence signal measured through skin. *Lasers Surg Med* 2001;**29**:213-20.
18. Cordoba J, Blei AT. Cerebral edema and intracranial pressure monitoring. *Liver Transplantation and Surgery* 1995;**1**:187-94.
19. Popovic EA, Kaye AH, Hill JS. Photodynamic therapy of brain tumors. *Journal of clinical laser medicine & surgery* 1996;**14**:251-61.
20. Wang J, Ozden I, Diagne M, Wagner F, Borton D, et al. Approaches to optical neuromodulation from rodents to non-human primates by integrated optoelectronic devices. *Proc Conf Proc IEEE Eng Med Biol Soc* 2011:7525-8.